Melanoma Matters23 Joulu 2024

Ep 56: Best of 2024: ASCO

Summary

Verbalizing punctuation for laughs...background wood noises ... and out of office replies get things started.

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel record their first in a series of "Best of 2024" and review highlights from the ASCO Annual Meeting. They focus on 4 significant trials: NADINA, COMBI-AD, KEYNOTE 942, and RELATIVITY 048.

James & Sapna discuss the implications of these studies on the melanoma landscape, the importance of long-term follow-up data, and share some light-hearted moments about out-of-office messages.

Keywords

ASCO 2024, melanoma, NADINA trial, neoantigen therapy, checkpoint blockade, out of office messages, long-term follow-up, immunotherapy

Takeaways

Out-of-office messages can be creative and memorable.

The NADINA trial showed a high major pathologic response rate of 60%.

Patient inclusion and trial design in clinical trials can critically affect outcomes (COMBI-AD).

The KEYNOTE 942 trial demonstrated encouraging trends for overall survival.

Triplet checkpoint blockade shows promising PFS results (RELATIVITY 048).

Titles

ASCO 2024 Highlights: Melanoma Trials Reviewed

NADINA, COMBI-AD, KN 942, RELA 048

Chapters

00:00 Introduction and Icebreakers

06:24 ASCO 2024 Highlights: NADINA Trial

13:39 Long-Term Follow-Up: COMBI-AD Study

21:16 Individualized Neoantigen Therapy: KEYNOTE 942

30:23 Triplet Checkpoint Blockade: RELATIVITY 048

31:11 Fact Check Best of 2024: ASCO

31:16 FDA Guidelines on Phase 3 Trials (Listening Series)

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(87)

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Kesä 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Kesä 1h 4min

Live from ASCO 2026: a preview

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting.OptimUM-02ADAMKN-942Neoadjuvant pilot studies... and more

1 Kesä 6min

Ep 81: IGNYTE trial (RP1 + nivo)

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into cli...

13 Helmi 32min

Ep 80: 2025 Holiday Special

SummaryHappy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music...

30 Joulu 202535min

Ep 79: coBRIM, COMBI-d 5-year follow-up

SummaryIn this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-...

29 Joulu 202536min

Ep 78 TRAILER: MEK inhibitor trials

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

29 Joulu 20251min

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)

SummarySo many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib...

29 Joulu 202537min